Tscan Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$1.06(as of May 22, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Tscan Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$1.06
Ticker SymbolTCRX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees142
CountyUSA
Market Cap$69.3M
EBIDTA-123.8M
10-Day Moving Average1.06
P/E Ratio-1.11
20-Day Moving Average1.14
Forward P/E Ratio0.00
50-Day Moving Average1.11
Earnings per Share-0.96
200-Day Moving Average1.34
Profit Margin-2,919.14%
RSI45.26
Shares Outstanding61.1M
ATR0.09
52-Week High2.57
Volume676,300
52-Week Low0.88
Most Recent Support Level0.95
Book Value96.9M
Most Recent Resistance Level1.34
P/B Ratio1.42
Upper Keltner1.34
P/S Ratio15.07
Lower Keltner0.95
Debt-to-Equity Ratio1.34
Next Earnings Date08/10/2026
Cash Surplus108.1M
Next Ex-Dividend DateUnknown

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Tscan Therapeutics Inc In Our Stock Scanner

As of May 22, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.